DelveInsight’s “Ocular Hypertension Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ocular Hypertension, historical and forecasted epidemiology as well as the Ocular Hypertension market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Ocular Hypertension market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Ocular Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ocular Hypertension Market Insights
Ocular Hypertension Overview
Ocular Hypertension (OHT) is a term used to describe intraocular pressure (IOP) greater than 21 mm Hg in one or both eyes in the absence of clinical evidence of optic nerve damage, visual field defect. OHT is the main risk factor for developing glaucoma and, therefore, people with ocular hypertension are more likely to suffer the disease.
Some of the key facts of the Ocular Hypertension Market Report:
- The Ocular Hypertension market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- The total prevalent cases of Ocular Hypertension were 20,960,514 cases in the 7MM
- The United States accounted for the highest number of prevalent cases in the 7MM in 2021 which are anticipated to increase further by 2032
- According to Saboo et al., study, the prevalence of ocular hypertension in the general population of ranges between 2.7–3.8% in the United States
- Key Ocular Hypertension Companies: Nicox Ophthalmics, Ocuphire Pharma, Santen Inc., Ono Pharmaceutical, Santen Inc., SPARC, Visiox Pharma, and others
- Key Ocular Hypertension Therapies: NCX 470, Nyxol, DE-126, DE-117, PDP-716, and others
- The Ocular Hypertension epidemiology based on gender analyzed that females are affected more than males
Get a Free sample for the Ocular Hypertension Market Report-
https://www.delveinsight.com/sample-request/ocular-hypertension-market
Key benefits of the Ocular Hypertension Market report:
- Ocular Hypertension market report covers a descriptive overview and comprehensive insight of the Ocular Hypertension Epidemiology and Ocular Hypertension market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Ocular Hypertension market report provides insights on the current and emerging therapies.
- Ocular Hypertension market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Ocular Hypertension market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Ocular Hypertension market.
Download the report to understand which factors are driving Ocular Hypertension epidemiology trends @ Ocular Hypertension Epidemiological Insights
Ocular Hypertension Market
The dynamics of the Ocular Hypertension market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
“Of the emerging therapies, DE-117 (Santen Pharmaceutical); PDP-716 (Sun Pharma); Sepetaprost(DE-126/ONO-9054) (Santen/Ono Pharmaceutical); NCX 470 (Nicox Ophthalmics), and Nyxol (Ocuphire Pharma) are compelling treatments. They are expected to change the ocular hypertension (OHT) market scenario in the upcoming years.”
Ocular Hypertension Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Ocular Hypertension Epidemiology Segmentation:
The Ocular Hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Ocular Hypertension
- Prevalent Cases of Ocular Hypertension by severity
- Gender-specific Prevalence of Ocular Hypertension
- Diagnosed Cases of Episodic and Chronic Ocular Hypertension
Ocular Hypertension Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ocular Hypertension market or expected to get launched during the study period. The analysis covers Ocular Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ocular Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Ocular Hypertension market share @ Ocular Hypertension market forecast
Ocular Hypertension Therapies and Key Companies
- NCX 470: Nicox Ophthalmics
- Nyxol: Ocuphire Pharma
- DE-126: Santen Inc. /Ono Pharmaceutical
- DE-117: Santen Inc.
- PDP-716: SPARC/Visiox Pharma
Ocular Hypertension Market Drivers
- Development of Better Diagnostic Techniques
- Active Research and Development activities
- Introduction of Personalized Medicine
- Innovative Approaches to Therapy Development
Scope of the Ocular Hypertension Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Ocular Hypertension Companies: Nicox Ophthalmics, Ocuphire Pharma, Santen Inc., Ono Pharmaceutical, Santen Inc., SPARC, Visiox Pharma, and others
- Key Ocular Hypertension Therapies: NCX 470, Nyxol, DE-126, DE-117, PDP-716, and others
- Ocular Hypertension Therapeutic Assessment: Ocular Hypertension current marketed and Ocular Hypertension emerging therapies
- Ocular Hypertension Market Dynamics: Ocular Hypertension market drivers and Ocular Hypertension market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Ocular Hypertension Unmet Needs, KOL’s views, Analyst’s views, Ocular Hypertension Market Access and Reimbursement
Ocular Hypertension Market Barriers
- Ocular Hypertension Treatment Associated Shortcomings
- Absence of Standard Guidelines
- Patient Adherence
Table of Contents
1. Ocular Hypertension Market Report Introduction
2. Executive Summary for Ocular Hypertension
3. SWOT analysis of Ocular Hypertension
4. Ocular Hypertension Patient Share (%) Overview at a Glance
5. Ocular Hypertension Market Overview at a Glance
6. Ocular Hypertension Disease Background and Overview
7. Ocular Hypertension Epidemiology and Patient Population
8. Country-Specific Patient Population of Ocular Hypertension
9. Ocular Hypertension Current Treatment and Medical Practices
10. Ocular Hypertension Unmet Needs
11. Ocular Hypertension Emerging Therapies
12. Ocular Hypertension Market Outlook
13. Country-Wise Ocular Hypertension Market Analysis (2019–2032)
14. Ocular Hypertension Market Access and Reimbursement of Therapies
15. Ocular Hypertension Market Drivers
16. Ocular Hypertension Market Barriers
17. Ocular Hypertension Appendix
18. Ocular Hypertension Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Ocular Hypertension treatment, visit @ Ocular Hypertension Medications
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting